Leerink Partners’ Post

At close, the Sensex was up 612.21 points, at 71,752.11, and the Nifty was up 203.60 points, at 21,725.70. Check out today's #TopStocks in the Nifty #Pharma Disclaimer- https://lnkd.in/gJJDnvn2 #stockmarket #stockmarketnews #stockmarketindia #stockmarketupdate #AliceBlue #NSE #BSE #MCX #market

M&As are making waves. 🌊 If you're caught in middle, now is the time to explore new partnerships. As a nimble CDMO, American Injectables offers immediate capacity and long-term collaboration. Exploring your options? Let's talk. https://hubs.li/Q02JD6lX0 #CDMO #Partnership #PharmaceuticalManufacturing #SterileInjectables #SupplyChainResilience

Dealmaking is picking up... Following a downturn in M&A activity during 2022 and 2023, the biopharma industry is increasing its level of dealmaking. Dive in: https://ow.ly/rPZJ30sCOX8

At the day's close on December 2, the Sensex was down 379.46 points at 71,892.48, and the Nifty was down 76.10 points at 21,665.80. Check out today's #TopStocks in the Nifty #Pharma sector Disclaimer- https://lnkd.in/gJJDnvn2 #stockmarket #stockmarketnews #stockmarketindia #stockmarketupdate #AliceBlue #NSE #BSE #MCX #market

Thoughts on this? >> Acorda files for bankruptcy, agrees to sell MS drug and other assets to Merz for $185M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #productmarketing #pharmaceutical

🚀 EYPT Soars 20% in One Day—Here’s How! 📈 On August 20th, an insider bought $25,000 worth of Eyepoint Pharmaceuticals Inc (EYPT), increasing their holdings by 3%. The very next day, the stock ripped from $7.93 to $9.05—a 10-15% gain in just a few hours, and nearly 20% by day’s end! 🔥 Want to catch these insider moves before they explode? Sign up for your FREE 14-day trial now and start trading like the pros. 👉 https://lnkd.in/ebtGheuu #InsiderTrading #StockGains #EYPT #DayTrading #FastProfits #TradeAlerts

According to BioWorld News, January biopharma deals exceed $26B, marking sixth-highest month Biopharma deals in January reached $26.97 billion, marking the sixth-highest month in BioWorld’s records going back to 2016. It is an increase of nearly 25% from the $21.64 billion in deals in January 2023 and also is up from December. Value the first month of the year is more than 2023’s average monthly value of $18.14 billion, and likewise more than the average monthly value of any previous year. While M&As are up 132.61% from January 2023’s $2.8 billion, the $6.52 billion value in the first month of 2024 falls short of December 2023’s $52.02 billion and the 2023 average of $11.65 billion per month.

Hello Connections!! Here is the snapshot of the details of the IPO of EMCURE Pharma. Please have a look at it. Also this is my first post on LinkedIn,so your feedbacks are welcomed so that it will help to Learn and Grow.. #Finance #StockMarket #EquityReasearch

$MRK recent adjustment to profit guidance opens up new opportunities for growth. Keep an eye on how this could impact their market position and investment potential: https://ibn.fm/PpsC1 #Merck #ProfitGuidance #MarketOpportunities #Investing #Pharma

Four buyouts (and one rumor that didn’t materialize); Isomorphic Labs' first pharma deals; A CAR-T IPO; #JPM24 highlights; and more >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #healthcare #pharmaceutical #pharma